MedTrace Logo

A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

NCT07705308 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-07-15

No results posted yet for this study

Summary

Multi center, randomized, controlled, prospective clinical trial to explore the clinical efficacy and safety of low-dose radiotherapy combined with targeted therapy for localized MALT lymphoma.

Conditions

  • Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

Interventions

RADIATION

Radiation (Very low dose)

4 Gy in 2 consecutive daily fractions subsequently with orelabrutinib

RADIATION

Radiation (Standard)

24 Gy in 12 fractions

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Shu-Bei Wang, MD · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-08-01
Completion
2031-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07705308 on ClinicalTrials.gov